New tech drives huge growth in vaccine business

A revolution in genomics and molecular biology has spurred a burst of new development activity in the vaccines business. Analysts say that a slew of new products will propel 18 percent annual growth in the sector as the vaccine business swells from $13 billion to $30 billion in 2011. Merck, AstraZeneca, Pfizer and Sanofi-Aventis are all pursuing ambitious new programs.

- read the article from Forbes on the vaccine revolution

Related Articles:
Big Pharma takes an interest in cancer vaccines. Report
New approach to vaccine development. Report
Vaccine "renaissance" attracts huge new venture investments. Report